Project Grant K99CA300907
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$139K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Washington, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $380,337 to the University of Washington to develop machine learning approaches and massively parallel reporter assays (MPRAs) to optimize mRNA sequences for cancer immunotherapy. The goal is to build predictive models that relate mRNA sequence to stability and translation, and then use these models to generate synthetic 5' and 3' untranslated regions (UTRs) and coding sequences (CDS)...
The National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), awarded a $632,906 Project Grant to Tulane University to study a novel role for the androgen receptor (AR) in prostate cancer progression and therapeutic resistance. The 5-year grant, which commenced on April 1, 2025, aims to elucidate how AR's RNA-binding activity promotes the expression of splicing factors, leading to efficient splicing and expression of genes critical for prostate cancer...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $552,968 to the University of Pittsburgh to conduct research on the role of tRNA modifications in glioblastoma stem cell maintenance and translational reprogramming. The research aims to understand how metabolic regulation of tRNA modification enzymes and amino acid availability impacts tRNA landscapes and codon-biased translation in glioblastoma, a highly lethal form of brain cancer....
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $415,902 to the University of Massachusetts Boston to conduct research aimed at overcoming lineage plasticity and therapy resistance in castration-resistant prostate cancer. The key objectives are to: Determine if expression of the FOXA2 transcription factor can drive luminal prostate cancer cells into a multilineage transition state. This will involve assessing FOXA2 chromatin binding...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $509,246 to the Regents of the University of Michigan to conduct research on early drivers of prostate cancer lineage plasticity. The key objectives are to: Determine the mechanisms by which transcriptional regulators modulate prostate cancer cell differentiation and hallmarks. Understand how these transcriptional regulators are upregulated in human prostate tumors and their association...
This Project Grant award of $683,979 from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), supports research by Weill Medical College of Cornell University to investigate the molecular mechanisms underlying prostate cancer progression and therapeutic resistance. The research aims to define how specific genetic alterations, particularly mutations in the SPOP gene, impact prostate cancer cell lineage fidelity and shape the development of...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $564,543 to Weill Medical College of Cornell University to conduct research on the role of the androgen receptor (AR) in prostate cancer. The research aims to: Determine the context that allows engagement of growth suppressive AR transcriptional programs in prostate cancer. Establish the translational implications of oncogenic and growth suppressive AR programs in...
The federal Project Grant award of $104,101 was provided by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The funding supports the research of Dr. Joshua Lang and Dr. Jamie Sperger at the University of Wisconsin-Madison to develop novel liquid biopsy assays for prostate cancer. Specifically, the researchers are working to leverage liquid biopsies to better understand which patients may benefit from TROP-2 targeted therapies and to...
The federal Project Grant award, ID HT94252411040, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The $879,692 award, with a performance period from September 30, 2024 to September 29, 2027, supports the Fred Hutchinson Cancer Center's research on "Combinatorial Phenotype-Targeted Therapy to Overcome Mechanisms Driving Prostate Cancer Treatment Resistance." This innovative research project aims to develop novel...
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research to study translation regulation in glioblastoma stem-like cells (GSCs) and its role in hypoxia adaptation. The $107,948 award to Case Western Reserve University aims to develop a better understanding of how translational regulation, as opposed to transcriptional regulation, allows GSCs to adapt to the hypoxic tumor environment and promote glioblastoma growth. The...